These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38676811)

  • 1. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
    Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
    J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Immune Reconstitution in ADA-Deficient Patients Treated With Elapegademase: A Real-World Experience.
    Murguia-Favela L; Suresh S; Wright NAM; Alvi S; Tehseen S; Hernandez-Trujillo V; Seroogy CM; Haddad E; Nieves D; Hershfield MS; Walter JE; Pettiford L; Kamani NR; Keller MD; Pham-Huy A; Grunebaum E
    J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1725-1733. PubMed ID: 36736953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of elapegademase and pegademase in ADA-deficient patients and mice.
    Murguia-Favela L; Min W; Loves R; Leon-Ponte M; Grunebaum E
    Clin Exp Immunol; 2020 May; 200(2):176-184. PubMed ID: 31989577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
    Dorsey MJ; Rubinstein A; Lehman H; Fausnight T; Wiley JM; Haddad E
    J Clin Immunol; 2023 Jul; 43(5):951-964. PubMed ID: 36840835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study.
    Onodera M; Uchiyama T; Ariga T; Yamada M; Miyamura T; Arizono H; Morio T
    Immun Inflamm Dis; 2023 Jul; 11(7):e917. PubMed ID: 37506145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
    Kohn DB; Gaspar HB
    J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
    Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
    J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
    Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
    J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM; Hershfield MS; Bahna SL
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.
    Moncada-Vélez M; Vélez-Ortega A; Orrego J; Santisteban I; Jagadeesh J; Olivares M; Olaya N; Hershfield M; Candotti F; Franco J
    Scand J Immunol; 2011 Nov; 74(5):471-81. PubMed ID: 21671975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
    Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
    Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National experience with adenosine deaminase deficiency related SCID in Polish children.
    Dąbrowska-Leonik N; Piątosa B; Słomińska E; Bohynikova N; Bernat-Sitarz K; Bernatowska E; Wolska-Kuśnierz B; Kałwak K; Kołtan S; Dąbrowska A; Goździk J; Ussowicz M; Pac M
    Front Immunol; 2022; 13():1058623. PubMed ID: 36685585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.